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FIGURE1.  Putative scenarios of tumor evolution after TKI therapy. Black circles, 
cells with EGFR activating mutation; red circles, cells with activating or resistant 
mutation; Black lines, different alleles; black arrowhead, activating mutation; red 
arrowhead, resistant mutation. TKI, tyrosine kinase inhibitor.
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To the Editor:
We read with interest a recent 
article by Nakamura et al.1 regarding 
noninvasive system for monitoring 
resistance to epidermal growth fac-
tor receptor (EGFr)-tyrosine kinase 
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inhibitors (TKIs) with plasma DNA. 
They showed a case with EGFR-mutant 
non–small-cell lung cancer in which the 
T790M-resistant mutation disappear 
after TKI-free interval with cytotoxic 
chemotherapy. We herein demonstrate 
a case with EGFR-mutant non–small-
cell lung cancer, where gefitinib rechal-
lenge was effective after disappearance 
of T790M.
A 66-year-old man having multi-
ple pulmonary nodules was referred to 
our institution. We performed a biopsy 
of the primary mass and diagnosed the 
patient as stage IV lung adenocarci-
noma. Irinotecan + S-1 and cisplatin 
+ docetaxel were sequentially admin-
istered. After these chemotherapies, 
EGFR mutation analysis became com-
mercially available. We examined the 
initial biopsy specimen using the pep-
tide nucleic acid-locked nucleic acid 
PCr clamp method; exon 19 deletional 
mutation and exon 21 L858r point 
mutation were detected. We therefore 
administered gefitinib as the third-line 
therapy. Partial response (Pr) was 
obtained, but the primary tumor pro-
gressed after 2 years. We performed 
a rebiopsy and L858r + T790M was 
revealed. We then administered cispla-
tin + S-1. Pr was obtained, but progres-
sion was confirmed after 1 year. We 
performed a second biopsy for the third 
time on the same tumor and detected 
only L858r; T790M had seemingly 
disappeared. Gefitinib was therefore 
rechallenged, and Pr was achieved (Fig. 
1A and 1B). Six months later, the pri-
mary tumor progressed again (Fig. 1C). 
We did a third rebiopsy and detected 
L858r + T790M again. Despite the 
detection of T790M, we have contin-
ued gefitinib beyond the progression, 
expecting an indolent course.
Did the T790M really disap-
pear in our present case? Chmielecki 
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et al.2 have demonstrated that T790M 
is mediated by TKI exposure, and TKI 
withdrawal reduces the proportion of 
T790M-harboring cells in an EGFR-
mutant tumor. We assume that the 
T790M did not disappear, but the 1-year 
TKI-free interval reduced the propor-
tion of T790M-harboring cells enough 
that T790M was undetectable by PCr. 
After gefitinib rechallenge, T790M 
was detected again. These phenomena 
suggest that both TKI-sensitive and 
TKI-resistant clones such as T790M-
harboring cells heterogeneously exist, 
and TKI exposure and TKI withdrawal 
can alter the proportion of each cell 
type (Fig. 2). This hypothesis has 
been recently proposed by oxnard et 
al.3 In their theory, resistant tumors 
are likely to be a mixed population of 
TKI-sensitive and TKI-resistant cells, 
and upon withdrawal of the selective 
pressure from TKI, previously arrested 
TKI-sensitive cells can repopulate 
more quickly than TKI-resistant cells, 
and tumors may regain their sensi-
tivity to TKI. This theory is based on 
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FIGURE 1.  (A) Chest computed tomography (CT) before the gefitinib rechallenge shows a primary tumor harboring L858R 
without T790M. (B) Chest CT after 2 months shows the primary tumor responding to gefitinib rechallenge. (C) Chest CT on 
progression shows the primary tumor harboring L858R + T790M.
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FIGURE 2.  (A) Initial EGFR-TKI-sensitive tumor consisting of L858R, del-19, and 
L858R + T790M cells. The major population was TKI-sensitive L858R cells. Del-
19 cells were a PCR-detectable minor population, and L858R + T790M cells were 
a PCR-undetectable extremely minor population. (B) The tumor responded to 
gefitinib. (C) The tumor with acquired resistance to TKI. L858R + T790M cells 
occupied a large proportion of the whole tumor. (D) After a TKI-free interval, 
TKI-sensitive L858R cells repopulated, with whole tumor progression. Conversely, 
L858R + T790M cells were reduced because of the TKI withdrawal, and the PCR 
did not detect T790M. (E) The tumor responded to gefitinib rechallenge. (F) Tumor 
regrowth after response to gefitinib rechallenge. L858R + T790M cells became 
dominant, and the PCR detected T790M again. The black arrows express TKI 
exposure, which results in increasing the proportion of T790M-positive cells. The 
white arrow expresses TKI withdrawal, which results in increasing the proportion 
of T790M-negative cells. del-19, deletional mutations in exon 19; EGFR, epidermal 
growth factor receptor; L858R, a point mutation in exon 21; PCR, polymerase chain 
reaction; T790M, a point mutation in exon 20; TKI, tyrosine kinase inhibitor.
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the indolent nature of T790M-positive 
TKI-resistant cells and the accelerated 
growth potential of T790M-negative 
TKI-sensitive cells.2,4
Sequist et al.5 also reported 
that two similar cases developed 
T790M at the time of TKI resistance 
and subsequently lost T790M in the 
same anatomical tumor after a TKI-
free interval. These patients both 
responded to a TKI rechallenge after 
losing the T790M.
Disappearance of T790M can be 
a predictive marker for the TKI rechal-
lenge in patients who harbored T790M 
at the previous rebiopsy. repeated 
biopsies, however, are challenging 
because of the tissue availability and 
procedural feasibility. Therefore, their 
noninvasive method to monitor T790M 
status is promising and warrants future 
studies.
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To the Editor:
I read with particular interest the 
recent article and accompanying edi-
torial on completeness of mediastinal 
lymph node dissection and survival in 
resected non–small-cell lung cancer.1,2 
As pointed out, the results come as a 
shock wave: in 62% of patients with 
pathologic N0 or N1 operated between 
1998 and 2002 in the Surveillance, 
Epidemiology, and End results data-
base, no formal mediastinal lymph 
node dissection was performed. In fact, 
none of these procedures qualifies for a 
complete r0 resection as defined by the 
International Association for the Study 
of Lung Cancer Staging Committee.
What is the current situation on 
this side of the Atlantic? In the European 
Society of Thoracic Surgeons database, 
the situation seems quite different: 
80% of patients undergo a systematic 
nodal dissection. however, it should 
be pointed out that this is a voluntary 
database from centers with a specific 
interest in thoracic surgery. Moreover, 
the large majority of data comes from 
France; so, there is clearly a shift toward 
one European country. Does this really 
reflect current practice all over Europe? 
Looking at studies specifically evaluat-
ing operative and pathological data in 
an independent way, the results are less 
encouraging, which even holds true for 
centers with a large experience in tho-
racic surgery and providing training in 
this specialty. In a recent study from the 
Netherlands, looking at four teaching 
hospitals of which one is a university 
hospital, the results are equally sur-
prising: in only 36% of the patients, 
at least three mediastinal lymph node 
stations were removed.3 Even more 
astonishing was the fact that a complete 
lymph node dissection according to the 
European Society of Thoracic Surgeons 
guidelines was performed in only 4% of 
patients. No significant difference was 
found between general surgeons with an 
additional certification in thoracic sur-
gery and cardiothoracic surgeons. This 
clearly implies that the pathological 
N classification cannot be considered 
to be accurate. Although these results 
were recorded in more recent years, 
they are very similar to those extracted 
from the Surveillance, Epidemiology, 
and End results database. Therefore, 
further teaching on this side of the 
Atlantic is certainly required.4 This was 
also concluded at a strategic meeting of 
the European Association for Cardio-
Thoracic Surgery, where completeness 
of lung cancer surgery was one of the 
discussion points.5 In this way, precise 
intraoperative staging during lung can-
cer surgery should remain a major topic 
of postgraduate courses, technocol-
leges, and teaching sessions organized 
by all major thoracic and cardiothoracic 
surgical societies.
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